Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 16 | 2022 | 791 | 5.040 |
Why?
|
| Pregnancy Complications, Infectious | 9 | 2021 | 92 | 3.740 |
Why?
|
| Trichomonas Vaginitis | 6 | 2020 | 25 | 2.800 |
Why?
|
| Trichomonas vaginalis | 5 | 2020 | 22 | 2.710 |
Why?
|
| Pregnancy | 21 | 2022 | 2334 | 1.760 |
Why?
|
| Chlamydia | 2 | 2022 | 5 | 1.610 |
Why?
|
| Gonorrhea | 3 | 2022 | 50 | 1.570 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2021 | 35 | 1.450 |
Why?
|
| Hepatitis C, Chronic | 2 | 2021 | 86 | 1.340 |
Why?
|
| Chlamydia Infections | 3 | 2021 | 41 | 1.320 |
Why?
|
| Anti-HIV Agents | 3 | 2021 | 135 | 1.300 |
Why?
|
| Premature Birth | 2 | 2021 | 150 | 1.250 |
Why?
|
| Metronidazole | 3 | 2021 | 28 | 1.170 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2022 | 300 | 1.130 |
Why?
|
| Mass Screening | 6 | 2022 | 843 | 1.130 |
Why?
|
| Family Planning Services | 2 | 2022 | 18 | 0.950 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2022 | 12 | 0.950 |
Why?
|
| Female | 35 | 2022 | 38074 | 0.890 |
Why?
|
| Retrospective Studies | 12 | 2022 | 7277 | 0.830 |
Why?
|
| South Carolina | 8 | 2022 | 2752 | 0.790 |
Why?
|
| Hepatitis C | 1 | 2021 | 114 | 0.720 |
Why?
|
| Chlamydia trachomatis | 3 | 2016 | 26 | 0.700 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2019 | 4 | 0.680 |
Why?
|
| Intrauterine Devices | 1 | 2019 | 15 | 0.670 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2019 | 6 | 0.660 |
Why?
|
| Humans | 36 | 2022 | 68618 | 0.650 |
Why?
|
| Adult | 21 | 2022 | 21403 | 0.630 |
Why?
|
| Abortion, Induced | 2 | 2009 | 18 | 0.620 |
Why?
|
| Rural Population | 3 | 2018 | 398 | 0.610 |
Why?
|
| Infant, Newborn | 7 | 2022 | 2455 | 0.600 |
Why?
|
| Maternal Health Services | 1 | 2017 | 22 | 0.590 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 30 | 0.560 |
Why?
|
| HIV Seropositivity | 2 | 2014 | 66 | 0.560 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 14 | 0.550 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 106 | 0.540 |
Why?
|
| Anti-Infective Agents | 2 | 2014 | 166 | 0.500 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 298 | 0.490 |
Why?
|
| Viral Load | 4 | 2022 | 127 | 0.490 |
Why?
|
| HIV-1 | 1 | 2016 | 177 | 0.490 |
Why?
|
| Quality of Health Care | 1 | 2017 | 322 | 0.480 |
Why?
|
| Young Adult | 10 | 2022 | 5717 | 0.470 |
Why?
|
| Uterine Cervicitis | 1 | 2014 | 18 | 0.470 |
Why?
|
| Cohort Studies | 5 | 2022 | 2358 | 0.460 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 445 | 0.460 |
Why?
|
| Infant | 4 | 2022 | 2891 | 0.450 |
Why?
|
| Leukorrhea | 1 | 2013 | 6 | 0.450 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 581 | 0.450 |
Why?
|
| Papillomaviridae | 1 | 2014 | 104 | 0.440 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 85 | 0.410 |
Why?
|
| Risk Factors | 7 | 2020 | 5731 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 1026 | 0.400 |
Why?
|
| Anus Neoplasms | 1 | 2012 | 37 | 0.400 |
Why?
|
| Integrases | 2 | 2022 | 31 | 0.400 |
Why?
|
| Prevalence | 3 | 2021 | 1619 | 0.390 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 194 | 0.380 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 454 | 0.370 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2010 | 37 | 0.360 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2009 | 11 | 0.340 |
Why?
|
| Postpartum Period | 2 | 2021 | 67 | 0.340 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 168 | 0.330 |
Why?
|
| Anesthesia, General | 1 | 2009 | 86 | 0.320 |
Why?
|
| Hysterotomy | 1 | 2007 | 1 | 0.290 |
Why?
|
| Pain, Postoperative | 1 | 2009 | 214 | 0.290 |
Why?
|
| Laparotomy | 1 | 2007 | 65 | 0.280 |
Why?
|
| Uterus | 1 | 2007 | 77 | 0.280 |
Why?
|
| RNA, Viral | 2 | 2017 | 93 | 0.270 |
Why?
|
| United States | 8 | 2022 | 7367 | 0.250 |
Why?
|
| Logistic Models | 2 | 2019 | 1420 | 0.250 |
Why?
|
| Cost-Benefit Analysis | 4 | 2014 | 504 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3259 | 0.230 |
Why?
|
| Oxazines | 2 | 2021 | 10 | 0.230 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2021 | 11 | 0.230 |
Why?
|
| Coercion | 1 | 2022 | 11 | 0.220 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 13 | 0.210 |
Why?
|
| Sentinel Surveillance | 1 | 2022 | 20 | 0.210 |
Why?
|
| Contraception | 1 | 2022 | 27 | 0.210 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2022 | 9 | 0.210 |
Why?
|
| Trichomonas Infections | 1 | 2021 | 14 | 0.200 |
Why?
|
| Vaginosis, Bacterial | 1 | 2021 | 24 | 0.200 |
Why?
|
| Time Factors | 3 | 2019 | 4655 | 0.190 |
Why?
|
| Perception | 1 | 2022 | 189 | 0.190 |
Why?
|
| Hepacivirus | 1 | 2021 | 90 | 0.190 |
Why?
|
| Pregnant Women | 1 | 2021 | 50 | 0.180 |
Why?
|
| Counseling | 1 | 2022 | 280 | 0.180 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 11 | 0.180 |
Why?
|
| Prenatal Care | 1 | 2021 | 117 | 0.180 |
Why?
|
| Antiviral Agents | 1 | 2021 | 211 | 0.170 |
Why?
|
| Birth Intervals | 1 | 2019 | 4 | 0.170 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1753 | 0.170 |
Why?
|
| Postnatal Care | 1 | 2019 | 16 | 0.170 |
Why?
|
| Women's Health | 1 | 2020 | 148 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2018 | 2007 | 0.170 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 157 | 0.160 |
Why?
|
| Incidence | 2 | 2014 | 1603 | 0.160 |
Why?
|
| Middle Aged | 6 | 2020 | 21147 | 0.160 |
Why?
|
| North Carolina | 1 | 2019 | 224 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2019 | 411 | 0.150 |
Why?
|
| Maternal Health | 1 | 2017 | 8 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2021 | 413 | 0.150 |
Why?
|
| Intimate Partner Violence | 1 | 2018 | 58 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 98 | 0.140 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2014 | 35 | 0.140 |
Why?
|
| Vagina | 1 | 2016 | 88 | 0.140 |
Why?
|
| Sex Offenses | 1 | 2018 | 170 | 0.140 |
Why?
|
| HIV | 1 | 2016 | 56 | 0.130 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2016 | 28 | 0.130 |
Why?
|
| Crime Victims | 1 | 2018 | 286 | 0.130 |
Why?
|
| Papanicolaou Test | 1 | 2015 | 54 | 0.130 |
Why?
|
| Vaginal Smears | 1 | 2015 | 79 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1745 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2015 | 123 | 0.120 |
Why?
|
| Vaginitis | 1 | 2014 | 21 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 106 | 0.120 |
Why?
|
| Tanzania | 1 | 2014 | 35 | 0.120 |
Why?
|
| Coinfection | 1 | 2014 | 30 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 800 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2021 | 7029 | 0.110 |
Why?
|
| Parasitology | 1 | 2013 | 4 | 0.110 |
Why?
|
| Exudates and Transudates | 1 | 2013 | 25 | 0.110 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 21 | 0.110 |
Why?
|
| Intention | 1 | 2014 | 80 | 0.110 |
Why?
|
| Lung Diseases, Fungal | 1 | 2012 | 6 | 0.110 |
Why?
|
| Microscopy | 1 | 2013 | 64 | 0.110 |
Why?
|
| Toxoplasmosis | 1 | 2012 | 13 | 0.110 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 19 | 0.110 |
Why?
|
| Circumcision, Male | 1 | 2012 | 12 | 0.110 |
Why?
|
| Aged | 3 | 2020 | 14862 | 0.110 |
Why?
|
| Syphilis | 1 | 2012 | 15 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2012 | 31 | 0.110 |
Why?
|
| Proctoscopy | 1 | 2012 | 4 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 191 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2012 | 61 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 53 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 772 | 0.100 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.100 |
Why?
|
| Lamivudine | 1 | 2011 | 24 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 618 | 0.100 |
Why?
|
| Obstetric Labor, Premature | 1 | 2012 | 76 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 320 | 0.100 |
Why?
|
| Decision Trees | 1 | 2011 | 74 | 0.100 |
Why?
|
| Adolescent | 4 | 2014 | 8912 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2011 | 42 | 0.100 |
Why?
|
| Reference Values | 1 | 2012 | 579 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2011 | 97 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 92 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 369 | 0.090 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2011 | 39 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4848 | 0.090 |
Why?
|
| Public Health | 1 | 2012 | 201 | 0.090 |
Why?
|
| Hysterectomy | 1 | 2010 | 64 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 156 | 0.090 |
Why?
|
| Medicaid | 1 | 2012 | 302 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.090 |
Why?
|
| Gravidity | 1 | 2009 | 11 | 0.090 |
Why?
|
| Survival Rate | 1 | 2012 | 1056 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 767 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2010 | 163 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 201 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2009 | 249 | 0.080 |
Why?
|
| Comorbidity | 1 | 2012 | 1426 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1040 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 378 | 0.070 |
Why?
|
| Hospitalization | 1 | 2010 | 978 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2016 | 39 | 0.060 |
Why?
|
| Gestational Age | 2 | 2016 | 389 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2010 | 1615 | 0.050 |
Why?
|
| Fluconazole | 1 | 2022 | 26 | 0.050 |
Why?
|
| Candida albicans | 1 | 2022 | 39 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2022 | 108 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2022 | 173 | 0.050 |
Why?
|
| Outpatients | 1 | 2020 | 127 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2018 | 106 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 340 | 0.040 |
Why?
|
| Male | 3 | 2014 | 37321 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1738 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 25 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2016 | 58 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 40 | 0.030 |
Why?
|
| Piperazines | 1 | 2016 | 206 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2015 | 281 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 649 | 0.030 |
Why?
|
| Urban Population | 1 | 2014 | 255 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 420 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2011 | 114 | 0.020 |
Why?
|
| Mycoplasma genitalium | 1 | 2011 | 4 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 113 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 110 | 0.020 |
Why?
|
| Mycoplasma Infections | 1 | 2011 | 40 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2012 | 284 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 346 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 448 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2279 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2800 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 931 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 3705 | 0.010 |
Why?
|